The Challenge: Dealing with an existing competitor launching a new product.
LucidQuest worked closely with a mid-size Pharma company to support them in better understanding the evolving IG landscape (in particular in the PID space) in key EU markets (DE, FR, IT), as an existing competitor was preparing for the launch of a new product.
The Action: Secondary and primary intelligence interviewing multiple stakeholders for a better understanding of competitors’ plans.
Our team conducted interviews with competitor company sources, API manufacturers and suppliers, and other market stakeholders, including HCPs and pharmacists, over three months to better understand the competitor’s plans. In the meantime, we did secondary research to provide a broader industry perspective to our client.
The Result: The company benefited from a well-informed response to the new threat.
At the end of the research period, LucidQuest prepared a comprehensive report containing insights on the competitor’s GTM and pricing plans for the new asset and information on KOL views in the different markets of interest.
Our client used these findings to inform their overall response to the new threat.
#primaryimmunodeficiency #PID #competitiveintelligence #immunoglobulintreatments #pharmastrategy #marketintelligence #casestudy #ourwork